Status | Study |
COMPLETED |
Study Name: HB0034 in Patients With Generalized Pustular Psoriasis (GPP) Condition: Generalized Pustular Psoriasis Date: 2022-08-22 Interventions: HB0034, a single dose |
Not yet recruiting |
Study Name: Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients Condition: Psoriasis Date: 2017-04-26 Interventions: Drug: BI 655130 (low dose) 12 |
Recruiting |
Study Name: A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis Condition: Moderate to Severe Psoriasis Generalized Pustular Psoriasis and Date: 2017-02-09 Interventions: Other: Placebo |
Recruiting |
Study Name: A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Condition: Generalized Pustular Psoriasis Erythrodermic Psoriasis Date: 2017-01-13 Interventions: Drug: risankizumab risankizumab administered by subcutaneous injection. |
Recruiting |
Study Name: BI655130 Single Dose in Generalized Pustular Psoriasis Condition: Psoriasis Date: 2016-11-29 Interventions: Drug: BI655130 |
Recruiting |
Study Name: An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis Condition: Palmoplantar Pustulosis Date: 2015-12-14 Interventions: Drug: Guselkumab Participants |
Active, not recruiting |
Study Name: Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) Condition: Generalized Pustular Psoriasis (GPP) Adalimumab Date: 2015-08-20 Interventions: Drug: Adalimumab Adalimumab |
Active, not recruiting |
Study Name: An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Condition: Pustular Psoriasis Date: 2015-01-16 Interventions: Drug: Guselkumab Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and |
Active, not recruiting |
Study Name: Palmoplantar Pustular Psoriasis Efficacy and Safety wIth Secukinumab Condition: Palmoplantar Pustular Psoriasis Date: 2013-12-08 Interventions: Biological: Secucinumab Secuci |
Completed |
Study Name: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) Condition: Psoriasis Date: 2013-09-24 Interventions: Biological: Secukinumab Secukinumab 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg |